Medical Properties (MPW) ended the recent trading session at $4.31, demonstrating a -3.36% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.52%. Elsewhere, the Dow saw an upswing of 0.63%, while the tech-heavy Nasdaq appreciated by 0.48%. Invest in Gold Priority Gold: Up to $15k in Free Silver + Zero Account Fees on Qualifying Purchase Learn More American Hartford Gold: #1 Precious Metals Dealer in the Nation Learn More Thor Metals Group: Best Overall Gold IRA Learn More Powered by Money.com - Yahoo may earn commission from the links above. Shares of the health care real estate investment trust witnessed a loss of 2.41% over the previous month, trailing the performance of the Finance sector with its gain of 2.2%, and the S&P 500's gain of 4.27%. Analysts and investors alike will be keeping a close eye on the performance of Medical Properties in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $0.13, reflecting a 43.48% decrease from the same quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $231.15 million, indicating a 13.29% decrease compared to the same quarter of the previous year. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.57 per share and a revenue of $930.43 million, indicating changes of -28.75% and -6.54%, respectively, from the former year. Investors should also take note of any recent adjustments to analyst estimates for Medical Properties. These recent revisions tend to reflect the evolving nature of short-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Medical Properties currently has a Zacks Rank of #2 (Buy). With respect to valuation, Medical Properties is currently being traded at a Forward P/E ratio of 7.87. This represents a discount compared to its industry average Forward P/E of 11.47. The REIT and Equity Trust - Other industry is part of the Finance sector. This industry, currently bearing a Zacks Industry Rank of 96, finds itself in the top 40% echelons of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Story Continues To follow MPW in the coming trading sessions, be sure to utilize Zacks.com. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medical Properties Trust, Inc. (MPW):Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments
Medical Properties (MPW) Stock Sinks As Market Gains: Here's Why
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...